Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 807 results for "bristol myers squibb"

Bristol-Myers To Unload $1.4 Billion Pension Liability
Bidness Etc

Bristol-Myers To Unload $1.4 Billion Pension Liability

Bristol-Myers will transfer pension obligations worth $1.4 billion to Prudential in order to reduce the risks associated with managing the pension plan. Other companies like General Motors and Verizon have also transferred their pension liabilities ... Bidness Etc, 16 hours ago
[x]  

137 images for bristol myers squibb

Jutia Group, 2 weeks ago
Pharma Letter, 3 weeks ago
Pensions and Investments Online, 9 hours ago
Pharma Letter, 4 weeks ago
Dividend.com, 1 month ago
Jutia Group, 1 month ago
Pharmafocus, 3 weeks ago
Pharmaceutical Executive, 3 weeks ago
I Stock Analyst, 1 week ago
I Stock Analyst, 1 week ago

Prudential Insurance Inks $1.4 Billion Pension Buy-Out With Bristol-Myers Squibb

In its second pension risk-transfer announcement in a week, Prudential Insurance Company of America will sell a group annuity contract to Bristol-Myers Squibb Co. as the pharmaceutical company said it will settle $1.4 billion in pension obligations ...
 Individual.com8 hours ago

Bristol-Myers to report on October 24

News Editor Bristol-Myers Squibb (BMY -1%) will report Q3 results on October 24. The conference call will begin at 10:30 am ET. Consensus view is EPS of $0.42 on revenues of $3.8B. Sent to 16,571 people who get email alerts on BMY. Get email ...
 Seeking Alpha14 hours ago Bristol Myers Squibb : Trademark Application for "LAMNETIQ" Filed by Bristol-Myers Squibb  4 Traders1 week ago Bristol Myers Squibb : An Application for the Trademark "THAT I CAN DO" Has Been Filed by Bristol-Myers Squibb  4 Traders1 week ago An Application for the Trademark "DASCERN" Has Been Filed by Bristol-Myers Squibb  Pharmacy Choice2 weeks ago
SPi World News

Bristol Myers Squibb : INNATE PHARMA : INITIATION OF A PHASE I CLINICAL TRIAL OF LIRILUMAB IN COMBINATION WITH ELOTUZUMAB

Initiation of a PHASE i clinical trial OF lirilumab IN COMBINATION WITH elotuzumab * This Phase I trial will test the safety and tolerability of lirilumab (BMS- 986015) in combination with elotuzumab (BMS-901608) in ...
 4 Traders16 hours ago INNATE PHARMA : INITIATION OF A PHASE I CLINICAL TRIAL OF LIRILUMAB IN COMBINATION WITH ELOTUZUMAB  Morningstar.com14 hours ago BRIEF-Innate Pharma announces Phase I trial of lirilumab in combination with elotuzumab  Reuters16 hours ago
[x]  

Potential Bristol Myers (BMY) Trade Targets 3.50% Return

For a hedged play on Bristol-Myers Squibb Co (http://www.marketintelligencecenter.com/symbol/BMY"BMY) MarketIntelligenceCenter.comaEUR(TM)s patented trade-picking algorithms selected a Jan. '15 $50.00 covered call for a net debit in the $48.31 area.
 Individual.com1 day ago Bristol Myers (BMY) Showing Bullish Technicals With Resistance At $52.41  PredictWallStreet2 days ago Bristol Myers (BMY) Trading Near $52.06 Resistance Level  Individual.com1 week ago Bristol Myers (BMY) Showing Support Near $51.16  Individual.com1 week ago

World Heart Federation Receives Donation from Bristol-Myers Squibb and Pfizer

The World Heart Federation reported a charitable donation from the pharmaceutical companies Bristol-Myers Squibb and Pfizer. According to a release from the group, the donation will support a program aimed at engaging patients with atrial ...
 Individual.com2 days ago BRISTOL MYERS SQUIBB : World Heart Federation Receives Donation from Bristol-Myers Squibb and Pfizer  4 Traders2 days ago Federação Mundial do Coração anuncia doação da Bristol-Myers Squibb e da Pfizer para um programa que ajuda a melhorar as experiências de pessoas com fibrilação atrial (FA)  PR Newswire6 days ago La World Heart Federation anuncia una donación de Bristol-Myers Squibb y Pfizer para la fibrilación ...  BioMedReports6 days ago
[x]  

Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment

Good news flowed in at Bristol-Myers Squibb Company ( BMY ) from the U.S. and EU with the regulatory authorities accepting the marketing applications for the company's high potential immuno-oncology candidate Opdivo (nivolumab, a PD-1 immune ...
 Yahoo! Finance2 days ago
[x]  

Gilead Sciences, Inc. Looks To Erase Bristol-Myers Squibb Company's Early Hep C Lead

Excitement is growing ahead of the Food and Drug Administration's decision on Gilead Sciences (NASDAQ: GILD ) next generation hepatitis C treatment. Most expect that the regulator will give the Sovaldi and ledipasvir combination drug the green ...
 BioSpace1 day ago Gilead Sciences, Inc. Takes Aim at Bristol-Myers Squibb  Motley Fool2 days ago

Bristol immune drug shows strong effect in melanoma study

(Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option. The ...
 Reuters2 days ago UPDATE 1-Bristol immune drug shows strong effect in melanoma study  Reuters2 days ago
[x]  

Ex-Dividend Reminder: ClubCorp Holdings, Bristol-Myers Squibb and Medtronic

Looking at the universe of stocks we cover at Dividend Channel, on 10/1/14, ClubCorp Holdings Inc (NYSE: MYCC), Bristol-Myers Squibb Co. (NYSE: MDT) will all trade ex-dividend for their respective upcoming dividends. ClubCorp Holdings Inc will pay ...
 Austin American Statesman2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less